Table 2 Study population distribution by cancer status based on the quartiles of ∑DEHP and metabolites; NHANES 2011–2018

∑DEHP

 < 0.001

  Q1: < 5.1 ng/mg crt

1417

103

6.8%

1520

24.7%

  Q2: 5.1–5.6 ng/mg crt

1397

141

9.2%

1538

25.0%

  Q3: 5.7–6.1 ng/mg crt

1380

166

10.7%

1546

25.2%

  Q4: > 6.1 ng/mg crt

1384

159

10.3%

1543

25.1%

p trend

MEHHP

 < 0.001

  Q1: < 3.6 ng/mg crt

1431

96

6.3%

1527

24.8%

  Q2: 3.6–4.1 ng/mg crt

1362

160

10.5%

1522

24.8%

  Q3: 4.2–4.6 ng/mg crt

1371

149

9.8%

1520

24.7%

  Q4: > 4.6 ng/mg crt

1414

164

10.4%

1578

25.7%

p trend

MEHP

0.222

  Q1: < 1.9 ng/mg crt

1377

142

9.3%

1519

24.7%

  Q2: 2.0–2.5 ng/mg crt

1393

156

10.1%

1549

25.2%

  Q3: 2.6–3.2 ng/mg crt

1392

148

9.6%

1540

25.1%

  Q4: > 3.2 ng/mg crt

1416

123

8.0%

1539

25.0%

p trend

MEOHP

 < 0.001

  Q1: < 3.1 ng/mg crt

1414

100

6.6%

1514

24.6%

  Q2: 3.1–3.6 ng/mg crt

1405

146

9.4%

1551

25.2%

  Q3: 3.7–4.2 ng/mg crt

1386

158

10.2%

1544

25.1%

  Q4: > 4.2 ng/mg crt

1373

165

10.7%

1538

25.0%

p trend

MECCP

0.002

  Q1: < 4.1 ng/mg crt

1418

107

7.0%

1525

24.8%

  Q2: 4.1–4.5 ng/mg crt

1386

138

9.1%

1524

24.8%

  Q3: 4.6–5.0 ng/mg crt

1396

157

10.1%

1553

25.3%

  Q4: > 5.0 ng/mg crt

1378

167

10.8%

1545

25.1%